Clinical efficacy of protein-bound polysaccharide K in patients with gastric cancer undergoing chemotherapy with an oral fluoropyrimidine (S-1)

被引：25

作者：

Namikawa, T. ^{[1
]}

Fukudome, I. ^{[1
]}

Ogawa, M. ^{[1
]}

Munekage, E. ^{[1
]}

Munekage, M. ^{[1
]}

Shiga, M. ^{[1
]}

Maeda, H. ^{[1
]}

Kitagawa, H. ^{[1
]}

Kobayashi, M. ^{[1
]}

Hanazaki, K. ^{[1
]}

机构：

[1] Kochi Med Sch, Dept Surg, Kochi 7838505, Japan

来源：

EJSO | 2015年 / 41卷 / 06期

关键词：

Gastric cancer; Immunochemotherapy; Neutrophil to lymphocyte ratio; Oral fluorouracil anticancer drug; Protein-bound polysaccharide-K; IMMUNOSUPPRESSIVE ACIDIC PROTEIN; PREDICTS POOR SURVIVAL; ADJUVANT IMMUNOCHEMOTHERAPY; PREOPERATIVE NEUTROPHIL; RATIO; LYMPHOCYTES; MORTALITY; CARCINOMA; RESECTION; PATTERNS;

D O I：

10.1016/j.ejso.2015.02.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Background: The aim of the present study was to evaluate the clinical significance of protein-bound polysaccharide K (PSK) in patients with primary gastric cancer who were being treated with an oral fluoropyrimidine (S-1). Methods: Clinical reports of 190 gastric cancer patients treated with S-1 chemotherapy, with or without PSK, at Kochi Medical School between 2007 and 2012 were investigated retrospectively to analyze survival. The neutrophil:lymphocyte ratio (NLR) was also evaluated as indicator of the immunoenhancing effect of PSK. Results: Overall survival was significantly longer in patients treated with S-1 + PSK than in those given S-1 alone (hazard ratio for death, 0.608; 95% confidence interval 0.375-0.985; P = 0.041). Furthermore, there was a tendency for changes in the NLR during chemotherapy to be lower in the S-1 + PSK group than in the S-1 group, but the difference did not reach statistical significance (P = 0.054). When patients were divided into groups based on preoperative NLR (i.e. <2.5 and >= 2.5), the mean (+/- SEM) NLR 1 month after the beginning of chemotherapy in the NLR >= 2.5 subgroup was significantly lower in patients treated with S-1 + PSK rather than S-1 alone (1.7 +/- 0.7 vs. 3.3 +/- 4.1, respectively; P = 0.043). Conclusions: Immunochemotherapy using PSK improves the survival of patients with advanced gastric cancer. The NLR may be a useful biomarker for evaluating prognosis in these patients. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：795 / 800

页数：6

共 24 条

[1]

The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment [J].